# US 2025/0019779 A1 · Polynucleotides for the amplification and detection of influenza a

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0019779 A1
- Document ID: US20250019779A1
- Status: Published application
- Kind: A1
- Application number: 18/444,250
- Filed: 2024-02-16
- Published: 2025-01-16
- Earliest claimed: 2021-08-18
- Assignees: Talis Biomedical Corporation
- Applicants: Talis Biomedical Corporation
- Inventors: William BROWN; Megan PRYCE; Yan ZHAO; Eduardo MORALES; James HART; Dan VANATTA; Andrea DEDENT; Josephine WONG; Doris COTO VILLA
- Web page: https://patentgrep.com/patent/US20250019779A1

## CPC

- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- C12Q 1/701: {Specific hybridization probes}
- C12Q 1/6818: involving interaction of two or more labels, e.g. resonant energy transfer
- C12Q 1/6844: Nucleic acid amplification reactions
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Methods, compositions, and kits are provided for the detection of Influenza A in a test sample. The presence or absence of Influenza A in the sample is determined by nucleic acid based assays using primers and/or probes with excellent sensitivity, specificity and inclusivity for detecting Influenza A strains and/or subtypes Detection strategies may utilize loop mediated isothermal amplification (LAMP) and molecular beacon hybridization.

## Claims

### Claim 1

A composition comprising a set of polynucleotides selected from the group consisting of Set-1 through Set-29.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a probe.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the probe comprises a label.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the probe is a labeled polynucleotide.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the labeled polynucleotide comprises one or more locked nucleic acids.

### Claim at position 6

-9. (canceled)

### Claim 10 (depends on 1)

The composition of claim 1, further comprising a labeled polynucleotide comprising a sequence selected from the group consisting of nucleotides 5-27 of SEQ ID NO: 53, nucleotides 5-27 of SEQ ID NO: 54, nucleotides 5-28 of SEQ ID NO: 55, nucleotides 5-27 of SEQ ID NO: 56, nucleotides 6-26 of SEQ ID NO: 57, nucleotides 5-27 of SEQ ID NO: 58, nucleotides 5-27 of SEQ ID NO: 59, and nucleotides 5-27 of SEQ ID NO: 60, and wherein the set of polynucleotides is selected from the group consisting of Set-1, Set-2, Set-3, Set-10, Set-11, Set-12, Set-13, Set-20, Set-21, Set-22, and Set-29.

### Claim 11

(canceled)

### Claim 12 (depends on 10)

The composition of claim 10, wherein the sequence of the labeled polynucleotides is SEQ ID NO: 60, and the set of polynucleotides is Set-3.

### Claim 13 (depends on 10)

The composition of claim 10, wherein the sequence of the labeled polynucleotides is SEQ ID NO: 60, and the set of polynucleotides is Set-10.

### Claim at position 11

-15. (canceled)

### Claim 16 (depends on 2)

The composition of claim 2, wherein the probe is a molecular beacon comprising a fluorophore, a quencher, and a polynucleotide.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The composition of claim 16, wherein the molecular beacon comprises a sequence selected from the group consisting of SEQ ID NO: 53 through SEQ ID NO: 64.

### Claim 19 (depends on 18)

The composition of claim 18, wherein the polynucleotide sequence consists of SEQ ID NO: 60.

### Claim 20

A molecular beacon comprising a fluorophore, a quencher, and a polynucleotide, wherein the polynucleotide comprises a sequence selected from the group consisting of nucleotides 5-27 of SEQ ID NO: 53, nucleotides 5-27 of SEQ ID NO: 54, nucleotides 5-28 of SEQ ID NO: 55, nucleotides 5-27 of SEQ ID NO: 56, nucleotides 6-26 of SEQ ID NO: 57, nucleotides 5-27 of SEQ ID NO: 58, nucleotides 5-27 of SEQ ID NO: 59, nucleotides 5-27 of SEQ ID NO: 60, nucleotides 8-28 of SEQ ID NO: 61, nucleotides 8-36 of SEQ ID NO: 62, nucleotides 8-26 of SEQ ID NO: 63, and nucleotides 10-26 of SEQ ID NO: 64.

### Claim 21 (depends on 20)

The molecular beacon of claim 20, wherein the polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO: 53 through SEQ ID NO: 64.

### Claim at position 18

-24. (canceled)

### Claim 25

A method of detecting Influenza A in a test sample, the method comprising:
(a) extracting nucleic acid from the test sample;
(b) amplifying a target sequence by reacting the nucleic acid extracted in step (a) with a reaction mixture comprising a strand displacement DNA polymerase and a sequence specific primer set, wherein said sequence-specific primer set is selected from the group consisting of Set-1 through Set-29; and
(c) detecting the presence or absence of an amplification product of step (b); wherein the presence of said amplification product is indicative of the presence of Influenza A in the test sample.

### Claim 25

(canceled)

### Claim 26 (depends on 25)

The method of claim 25, wherein the amplifying step is performed for less than fifteen minutes.

### Claim 27 (depends on 25)

The method of claim 25, wherein the amplifying step is performed for less than twelve minutes.

### Claim 28

(canceled)

### Claim 29 (depends on 25)

The method of claim 25, wherein the reaction mixture further comprises a reverse transcriptase.

### Claim 30 (depends on 25)

The method of claim 25, wherein the detecting the presence or absence of the amplification product in step (c) comprises hybridizing the amplification product with a probe comprising a polynucleotide attached to a label.

### Claim at position 26

-33. (canceled)

### Claim 34 (depends on 25)

The method of claim 25, further comprising a labeled polynucleotide comprising a sequence selected from the group consisting of nucleotides 5-27 of SEQ ID NO: 53, nucleotides 5-27 of SEQ ID NO: 54, nucleotides 5-28 of SEQ ID NO: 55, nucleotides 5-27 of SEQ ID NO: 56, nucleotides 6-26 of SEQ ID NO: 57, nucleotides 5-27 of SEQ ID NO: 58, nucleotides 5-27 of SEQ ID NO: 59, nucleotides 5-27 of SEQ ID NO: 60, nucleotides 8-28 of SEQ ID NO: 61, nucleotides 8-36 of SEQ ID NO: 62, nucleotides 8-26 of SEQ ID NO: 63, and nucleotides 10-26 of SEQ ID NO: 64.

### Claim at position 28

-37. (canceled)

### Claim 38 (depends on 34)

The method of claim 34, wherein the sequence of the labeled polynucleotides is SEQ ID NO: 60, and the set of polynucleotides is Set-3.

### Claim at position 30

-40. (canceled)

### Claim 41

A kit comprising a set of polynucleotides selected from the group consisting of Set-1 through Set-29.

### Claim 42 (depends on 41)

The kit of claim 41, further comprising a strand displacement polymerase.

### Claim 43 (depends on 42)

The kit of claim 42, further comprising a reverse transcriptase.

### Claim at position 34

-47. (canceled)

### Claim 48

A method of detecting Influenza A in a test sample, the method comprising:
(a) extracting nucleic acid from the test sample;
(b) amplifying a target sequence by reacting nucleic acid extracted in step (a) for less than fifteen minutes with a reaction mixture comprising a strand displacement DNA polymerase and a sequence-specific LAMP primer set; and
(c) detecting the presence or absence of an amplified product of step (b); wherein the presence of said amplification product is indicative of the presence of Influenza A in the test sample.

### Claim 49 (depends on 48)

The method of claim 48, wherein said sequence-specific primer set is selected from the group consisting of Set-1 through Set-29.

### Claim at position 37

-51. (canceled)
